Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Social Determinants of Health, Disease Burden, and Effects of Hidradenitis Suppurativa Across Various Racial and Ethnic Populations in the United States

  • By

  • Tarannum Jaleel

  • Raj Chovatiya

  • Elizabeth D. Bacci

  • Evangeline Pierce

  • Melissa L. Constantine

  • Julia R. Correll

  • Beth Mitchell

  • Dipak R. Patel

  • Brindley Brooks

  • Candrice Heath

  • Vivian Y. Shi

  • May 2, 2026

Share

Original Source(s)

Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USA

  • by Tarannum Jaleel, Raj Chovatiya, Elizabeth D. Bacci, Evangeline Pierce, Melissa L. Constantine, Julia R. Correll, Beth Mitchell, Dipak R. Patel, Brindley Brooks, Candrice Heath, Vivian Y. Shi

  • May 2, 2026

Related Content

Scrotal Elephantiasis Secondary to Hidradenitis Suppurativa: A Rare Case Report

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.